Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vobramitamab duocarmazine in mCRPC and solid tumors (Tamarack)
NCT05551117Phase 2Terminated
- Sponsor
- MacroGenics
- Start
- Jun 2023
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (mCRPC), anal cancer, head and neck squamous cell carcinoma (HNSCC) and 3 more, sponsored by MacroGenics. Primary endpoints: Six-month Radiographic Progression Free Survival at 6 months and Objective Response Rate at 10 months. Started Jun 2023; status: terminated.
02
Drugs
vobramitamab duocarmazine
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)anal cancerhead and neck squamous cell carcinoma (HNSCC)melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05551117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05551117.